Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026)

Oculis Holding AG's (OCS) quarterly Share-based Compensation came in at $6.4 million in Q1 2026, up 118.32% year-on-year from $2.9 million in Q1 2025, and up 18.37% quarter-over-quarter from $5.4 million in Q4 2025.

Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026) Analysis & Trends

Oculis Holding AG's Share-based Compensation history runs 5 years deep, the most recent figure standing at $6.4 million for Q1 2026.

  • On a quarterly basis, Share-based Compensation rose 118.32% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $23.0 million, a 80.81% increase from a year earlier, with the FY2025 full-year figure at $19.4 million, up 74.03% from the prior year.
  • Share-based Compensation grew to $6.4 million in Q1 2026 per OCS's latest filing, from $5.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $6.4 million in Q1 2026 and bottomed at $150513.2 in Q4 2022.
  • The 5-year median for Share-based Compensation is $2.9 million (2024), against an average of $2.8 million.
  • Across the five-year window, Share-based Compensation surged 733.86% in 2024 and soared 50.32% in 2025, its largest moves.
  • Year by year, Share-based Compensation stood at $150513.2 in 2022, then soared by 680.47% to $1.2 million in 2023, then jumped by 176.17% to $3.2 million in 2024, then surged by 66.3% to $5.4 million in 2025, then grew by 18.37% to $6.4 million in 2026.
  • Per Business Quant, the three latest OCS Share-based Compensation figures stand at $6.4 million (Q1 2026), $5.4 million (Q4 2025), and $5.7 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 6.39 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 3.20 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 9.26 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 166.40 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 257.40 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 87.30 Mn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 6.39 Mn
Mar 31, 2026 6.39 Mn
Dec 31, 2025 5.40 Mn
Dec 31, 2025 5.40 Mn
Sep 30, 2025 5.70 Mn
Sep 30, 2025 5.70 Mn
Jun 30, 2025 5.48 Mn
Jun 30, 2025 5.48 Mn
Mar 31, 2025 2.93 Mn
Mar 31, 2025 2.93 Mn
Dec 31, 2024 3.24 Mn
Dec 31, 2024 3.24 Mn
Sep 30, 2024 2.89 Mn
Sep 30, 2024 2.89 Mn
Jun 30, 2024 3.65 Mn
Jun 30, 2024 3.65 Mn
Mar 31, 2024 1.31 Mn
Mar 31, 2024 1.31 Mn
Dec 31, 2023 1.17 Mn
Dec 31, 2023 1.17 Mn